Close Menu

GSK

MDxHealth and GlaxoSmithKline Biologicals, both of Belgium, have been awarded US Patent No. 8,481,700, "Detection of MAGE-A expression."
Ilse Vlassenbroeck and Katja Bierau are named as inventors.

NEW YORK (GenomeWeb News) – The US Food and Drug Administration announced on Wednesday the approval of a companion diagnostic for two drugs that treat patients with advanced or unresectable melanoma.

Two new personalized treatment options are now available for patients with metastatic or unresectable melanoma whose tumors harbor mutations in the BRAF gene.

Regulus Therapeutics this week announced that it has selected its first drug candidate, RG-101 for the treatment of hepatitis C. However, the company said it will develop the compound on its own despite an ongoing collaboration on the disease with GlaxoSmithKline.

The Biological Research Center of the Hungarian Academy of Sciences and Glaxo Group Limited, a subsidiary of GlaxoSmithKline, have been jointly awarded US Patent No. 8,389,802, "Artificial chromosomes, uses thereof, and methods for preparing artificial chromosomes.

Officials from Regulus Therapeutics this week said that the company continues to plan on filing two investigational new drug applications in 2014, one of which is for a microRNA-122-targeting hepatitis C treatment, but fell short of promising the goal would be met.

Though not as advanced a therapeutic technology as its RNAi cousin, microRNA received a lot of positive attention from the investment community in 2012, with the top companies in the space pulling in nearly $150 million in financing dollars over the past year.

By law, Chinese samples cannot leave China. That fact has made Shanghai Biochip a partner for international pharmaceutical companies seeking to conduct various trials in the country.

Isis Pharmaceuticals this week announced that the US Food and Drug Administration has fast tracked its antisense-based transthyretin amyloidosis drug ISIS-TTRRx for use in patients with familial amyloid polyneuropathy, the rarer form of the disease.

The management of Regulus Therapeutics last week provided a few new details on the company's pipeline, promising that it would have two microRNA drug candidates ready for clinical trials before the end of next year.

Pages

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.

LiveScience reports that a novel mutation in the LPL gene was uncovered in three siblings with very high triglyceride levels.

The president of Nankai University is embroiled in a data manipulation scandal, the South China Morning Post reports.

In PNAS this week: cytotoxic CD4 T cell signature in supercentenarians, evolutionary history of beetles, and more.